Annual Accounts Receivable
$35.41 M
+$14.44 M+68.90%
December 31, 2023
Summary
- As of February 7, 2025, PHAR annual accounts receivable is $35.41 million, with the most recent change of +$14.44 million (+68.90%) on December 31, 2023.
- During the last 3 years, PHAR annual accounts receivable has risen by +$11.89 million (+50.58%).
- PHAR annual accounts receivable is now at all-time high.
Performance
PHAR Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$48.20 M
-$2.92 M-5.71%
September 30, 2024
Summary
- As of February 7, 2025, PHAR quarterly accounts receivable is $48.20 million, with the most recent change of -$2.92 million (-5.71%) on September 30, 2024.
- Over the past year, PHAR quarterly accounts receivable has increased by +$9.50 million (+24.55%).
- PHAR quarterly accounts receivable is now -5.71% below its all-time high of $51.12 million, reached on June 30, 2024.
Performance
PHAR Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
PHAR Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +68.9% | +24.6% |
| 3 y3 years | +50.6% | +166.7% |
| 5 y5 years | +101.8% | +63.3% |
PHAR Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +95.9% | -5.7% | +166.7% |
| 5 y | 5-year | at high | +95.9% | -5.7% | +166.7% |
| alltime | all time | at high | -100.0% | -5.7% | -100.0% |
Pharming Group NV Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $48.20 M(-5.7%) |
| Jun 2024 | - | $51.12 M(+32.1%) |
| Mar 2024 | - | $38.70 M(+9.3%) |
| Dec 2023 | $35.41 M(+68.9%) | $35.41 M(-12.6%) |
| Sep 2023 | - | $40.52 M(+22.2%) |
| Jun 2023 | - | $33.16 M(+0.7%) |
| Mar 2023 | - | $32.93 M(+57.1%) |
| Dec 2022 | $20.96 M(+16.0%) | $20.96 M(-27.3%) |
| Sep 2022 | - | $28.83 M(-12.3%) |
| Jun 2022 | - | $32.88 M(+4.6%) |
| Mar 2022 | - | $31.45 M(+74.0%) |
| Dec 2021 | $18.08 M(-23.1%) | $18.08 M(-44.9%) |
| Sep 2021 | - | $32.81 M(-12.7%) |
| Jun 2021 | - | $37.57 M(+14.2%) |
| Mar 2021 | - | $32.88 M(+39.8%) |
| Dec 2020 | $23.51 M(-18.5%) | $23.51 M(-24.3%) |
| Sep 2020 | - | $31.05 M(+4.6%) |
| Jun 2020 | - | $29.68 M(-12.0%) |
| Mar 2020 | - | $33.71 M(+16.8%) |
| Dec 2019 | $28.86 M(+64.5%) | $28.86 M(-2.2%) |
| Sep 2019 | - | $29.52 M(+5.5%) |
| Jun 2019 | - | $28.00 M(+9.4%) |
| Mar 2019 | - | $25.59 M(+45.9%) |
| Dec 2018 | $17.54 M(+64.4%) | $17.54 M(-36.0%) |
| Sep 2018 | - | $27.39 M(+41.2%) |
| Jun 2018 | - | $19.40 M(+9.5%) |
| Mar 2018 | - | $17.72 M(+66.0%) |
| Dec 2017 | $10.67 M | $10.67 M(-47.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $20.28 M(-4.9%) |
| Jun 2017 | - | $21.33 M(+0.6%) |
| Mar 2017 | - | $21.21 M(+221.1%) |
| Dec 2016 | $6.60 M(+186.8%) | $6.60 M(+0.3%) |
| Sep 2016 | - | $6.59 M(+6.7%) |
| Jun 2016 | - | $6.17 M(+40.5%) |
| Mar 2016 | - | $4.39 M(+90.8%) |
| Dec 2015 | $2.30 M(+170.1%) | $2.30 M(-50.5%) |
| Sep 2015 | - | $4.65 M(-2.6%) |
| Jun 2015 | - | $4.77 M(+85.7%) |
| Mar 2015 | - | $2.57 M(+201.6%) |
| Dec 2014 | $852.40 K(+192.5%) | $852.40 K(-59.7%) |
| Sep 2014 | - | $2.12 M(+19.2%) |
| Jun 2014 | - | $1.77 M(+119.9%) |
| Mar 2014 | - | $807.30 K(+177.0%) |
| Dec 2013 | $291.40 K(>+9900.0%) | $291.40 K(-51.9%) |
| Sep 2013 | - | $605.90 K(-91.4%) |
| Jun 2013 | - | $7.09 M(+724.5%) |
| Mar 2013 | - | $859.30 K(>+9900.0%) |
| Dec 2012 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sep 2012 | - | $1.27 M(-18.0%) |
| Mar 2012 | - | $1.55 M(+238.5%) |
| Dec 2011 | $457.50 K(-96.5%) | $457.50 K(-63.3%) |
| Sep 2011 | - | $1.25 M(+26.1%) |
| Jun 2011 | - | $990.20 K(+20.1%) |
| Mar 2011 | - | $824.60 K(-93.8%) |
| Dec 2010 | $13.21 M(+562.3%) | $13.21 M(+562.3%) |
| Dec 2009 | $1.99 M | $1.99 M |
FAQ
- What is Pharming Group NV annual accounts receivable?
- What is the all time high annual accounts receivable for Pharming Group NV?
- What is Pharming Group NV annual accounts receivable year-on-year change?
- What is Pharming Group NV quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Pharming Group NV?
- What is Pharming Group NV quarterly accounts receivable year-on-year change?
What is Pharming Group NV annual accounts receivable?
The current annual accounts receivable of PHAR is $35.41 M
What is the all time high annual accounts receivable for Pharming Group NV?
Pharming Group NV all-time high annual accounts receivable is $35.41 M
What is Pharming Group NV annual accounts receivable year-on-year change?
Over the past year, PHAR annual accounts receivable has changed by +$14.44 M (+68.90%)
What is Pharming Group NV quarterly accounts receivable?
The current quarterly accounts receivable of PHAR is $48.20 M
What is the all time high quarterly accounts receivable for Pharming Group NV?
Pharming Group NV all-time high quarterly accounts receivable is $51.12 M
What is Pharming Group NV quarterly accounts receivable year-on-year change?
Over the past year, PHAR quarterly accounts receivable has changed by +$9.50 M (+24.55%)